恩替卡韦-话题@MedSci

#恩替卡韦#

28篇内容 | 2054人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1368921, encodeId=e06b136892197, content=<a href='/topic/show?id=2d305285e9f' target=_blank style='color:#2F92EE;'>#恩替卡韦#</a>, objectTitle=恩替卡韦临床应用专家共识：2015年更新要点中国肝脏病杂志（电子版） , objectType=article, longId=54606, objectId=e5bb54606b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5bb54606b0, replyNumber=0, likeNumber=59, createdTime=2015-08-09, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5bb54606b0, moduleTitle=恩替卡韦临床应用专家共识：2015年更新要点中国肝脏病杂志（电子版） , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5bb54606b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368920, encodeId=2d581368920cb, content=<a href='/topic/show?id=2d305285e9f' target=_blank style='color:#2F92EE;'>#恩替卡韦#</a>, objectTitle=JAMA：预防淋巴瘤化疗患者乙肝复发，恩替卡韦or拉米夫定？, objectType=article, longId=44474, objectId=64a7444e472, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64a7444e472, replyNumber=0, likeNumber=66, createdTime=2014-12-24, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64a7444e472, moduleTitle=JAMA：预防淋巴瘤化疗患者乙肝复发，恩替卡韦or拉米夫定？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64a7444e472)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368919, encodeId=4b88136891961, content=<a href='/topic/show?id=2d305285e9f' target=_blank style='color:#2F92EE;'>#恩替卡韦#</a>, objectTitle=JAMA：抑制化疗患者HBV再激活？恩替卡韦显优势, objectType=article, longId=44347, objectId=fe834434eb5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe834434eb5, replyNumber=0, likeNumber=92, createdTime=2014-12-21, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe834434eb5, moduleTitle=JAMA：抑制化疗患者HBV再激活？恩替卡韦显优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe834434eb5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368918, encodeId=f52b1368918a2, content=<a href='/topic/show?id=2d305285e9f' target=_blank style='color:#2F92EE;'>#恩替卡韦#</a>, objectTitle=Gut：恩替卡韦不能消除乙肝患者的肝细胞癌风险, objectType=article, longId=38159, objectId=45a73815926, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45a73815926, replyNumber=0, likeNumber=47, createdTime=2014-07-25, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45a73815926, moduleTitle=Gut：恩替卡韦不能消除乙肝患者的肝细胞癌风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45a73815926)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368917, encodeId=1433136891e81, content=<a href='/topic/show?id=2d305285e9f' target=_blank style='color:#2F92EE;'>#恩替卡韦#</a>, objectTitle=Hepatology：长期恩替卡韦可有效治疗慢乙肝原发性无应答者, objectType=article, longId=35119, objectId=b7423511939, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7423511939, replyNumber=0, likeNumber=66, createdTime=2014-05-24, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7423511939, moduleTitle=Hepatology：长期恩替卡韦可有效治疗慢乙肝原发性无应答者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7423511939)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368916, encodeId=f9c6136891658, content=<a href='/topic/show?id=2d305285e9f' target=_blank style='color:#2F92EE;'>#恩替卡韦#</a>, objectTitle=不同剂量恩替卡韦对慢乙肝初治患者无显著差异, objectType=article, longId=29214, objectId=e94d2921435, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e94d2921435, replyNumber=0, likeNumber=55, createdTime=2014-01-11, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e94d2921435, moduleTitle=不同剂量恩替卡韦对慢乙肝初治患者无显著差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e94d2921435)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368915, encodeId=2542136891506, content=<a href='/topic/show?id=2d305285e9f' target=_blank style='color:#2F92EE;'>#恩替卡韦#</a>, objectTitle=Hepatology：香港中文大学Vincent WS Wong等发现AFP为诊断恩替卡韦治疗慢乙肝患者发生肝癌的特异性肿瘤标记物, objectType=article, longId=26581, objectId=4fb426581aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fb426581aa, replyNumber=0, likeNumber=0, createdTime=2013-11-15, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fb426581aa, moduleTitle=Hepatology：香港中文大学Vincent WS Wong等发现AFP为诊断恩替卡韦治疗慢乙肝患者发生肝癌的特异性肿瘤标记物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fb426581aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368914, encodeId=52c31368914ac, content=<a href='/topic/show?id=2d305285e9f' target=_blank style='color:#2F92EE;'>#恩替卡韦#</a>, objectTitle=J Viral Hepat：恩替卡韦+聚乙二醇干扰素序贯法治疗非HBV基因D型的高病毒血症慢性乙肝疗效更佳, objectType=article, longId=24014, objectId=720d2401409, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=720d2401409, replyNumber=0, likeNumber=64, createdTime=2013-09-08, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=720d2401409, moduleTitle=J Viral Hepat：恩替卡韦+聚乙二醇干扰素序贯法治疗非HBV基因D型的高病毒血症慢性乙肝疗效更佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=720d2401409)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368913, encodeId=d73b1368913ca, content=<a href='/topic/show?id=2d305285e9f' target=_blank style='color:#2F92EE;'>#恩替卡韦#</a>, objectTitle=APASL 2013：恩替卡韦长期抗病毒治疗降低HCC风险, objectType=article, longId=21705, objectId=738021e0540, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=738021e0540, replyNumber=0, likeNumber=76, createdTime=2013-07-21, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=738021e0540, moduleTitle=APASL 2013：恩替卡韦长期抗病毒治疗降低HCC风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=738021e0540)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368912, encodeId=2bb71368912e1, content=<a href='/topic/show?id=2d305285e9f' target=_blank style='color:#2F92EE;'>#恩替卡韦#</a>, objectTitle=恩替卡韦部分应答及耐药慢乙肝患者联合ADV治疗1例, objectType=article, longId=21378, objectId=f746213e822, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f746213e822, replyNumber=0, likeNumber=74, createdTime=2013-07-15, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f746213e822, moduleTitle=恩替卡韦部分应答及耐药慢乙肝患者联合ADV治疗1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f746213e822)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368911, encodeId=c96d1368911af, content=<a href='/topic/show?id=2d305285e9f' target=_blank style='color:#2F92EE;'>#恩替卡韦#</a>, objectTitle=ASCO 2013：黄河教授研究认为预防DLBCL乙肝再激活恩替卡韦疗效似更优, objectType=article, longId=19648, objectId=562019648ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=562019648ab, replyNumber=0, likeNumber=57, createdTime=2013-06-06, rootId=0, userName=smallant2002, userId=0a27288, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=562019648ab, moduleTitle=ASCO 2013：黄河教授研究认为预防DLBCL乙肝再激活恩替卡韦疗效似更优, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=562019648ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

恩替卡韦

2020-05-29

smallant2002 (审核中...)

前往app查看评论内容

#恩替卡韦#

恩替卡韦临床应用专家共识：2015年更新要点中国肝脏病杂志（电子版）

2015-08-09

smallant2002 (审核中...)

前往app查看评论内容

#恩替卡韦#

JAMA：预防淋巴瘤化疗患者乙肝复发，恩替卡韦or拉米夫定？

2014-12-24

smallant2002 (审核中...)

前往app查看评论内容

#恩替卡韦#

JAMA：抑制化疗患者HBV再激活？恩替卡韦显优势

2014-12-21

smallant2002 (审核中...)

前往app查看评论内容

#恩替卡韦#

Gut：恩替卡韦不能消除乙肝患者的肝细胞癌风险

2014-07-25

smallant2002 (审核中...)

前往app查看评论内容

#恩替卡韦#

Hepatology：长期恩替卡韦可有效治疗慢乙肝原发性无应答者

2014-05-24

smallant2002 (审核中...)

前往app查看评论内容

#恩替卡韦#

不同剂量恩替卡韦对慢乙肝初治患者无显著差异

2014-01-11

smallant2002 (审核中...)

前往app查看评论内容

#恩替卡韦#

Hepatology：香港中文大学Vincent WS Wong等发现AFP为诊断恩替卡韦治疗慢乙肝患者发生肝癌的特异性肿瘤标记物

2013-11-15

smallant2002 (审核中...)

前往app查看评论内容

#恩替卡韦#

J Viral Hepat：恩替卡韦+聚乙二醇干扰素序贯法治疗非HBV基因D型的高病毒血症慢性乙肝疗效更佳

2013-09-08

smallant2002 (审核中...)

前往app查看评论内容

#恩替卡韦#

APASL 2013：恩替卡韦长期抗病毒治疗降低HCC风险

2013-07-21

smallant2002 (审核中...)

前往app查看评论内容

#恩替卡韦#

恩替卡韦部分应答及耐药慢乙肝患者联合ADV治疗1例

2013-07-15

smallant2002 (审核中...)

前往app查看评论内容

#恩替卡韦#

ASCO 2013：黄河教授研究认为预防DLBCL乙肝再激活恩替卡韦疗效似更优

2013-06-06

科室
- - 订阅+
  - 更多科室
工具
服务